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Departments of Dermatology, University of Lund (BL & MB), Malmo, Sweden and Yale University School of Medicine (DMC), New Haven, 
Connecticut, U.S.A . 
Serum levels and skin photosensitivity following dif-
ferent oral doses of 8-methoxypsoralen (8-MOP) were 
studied in 8 healthy volunteers. Two hours after inges-
tion of drug, serum levels of 8-MOP determined by high 
pressure liquid chromatography correlated well with 
oral dose. Serum concentrations after 8-MOP doses of 
0.3, 0.6 and 0.9 mg/kg bodyweight were 25.9 (±7 .2), 148.9 
(±24.2) and 311.4 (±55.6) ng/ml (mean and SEM) respec-
tively. 
The minimal photo toxic dose (MPD) of UV A 2 hr after 
ingesting 8-MOP was determined in 6 volunteers for each 
of the 3 before-mentioned 8-MOP doses. The UV-A doses 
_correlated inversely with the serum level for each indi-
vidual (r = 0.92 ± 0.02 SEM). For higher 8-MOP doses 
the numerical product of UV-A dose and 8-MOP serum 
concentration in each individual tended to be constant, 
indicating a reciprocal relationship between 8-MOP and 
UV -A doses in this interval. This did not hold true for 
the lowest 8-MOP-dose. 
These data confirm the relevance of using 8-MOP blood 
level determinations in monitoring psoralen-UV-A pho-
totoxicity. 
Treatment with 8-methoxypsoralen (8-MOP) and long wave 
ultraviolet light (UV -A) in combination (PUVA), is highly 
effective in psoriasis [1,2]. 8-MOP interacts with nuclear DNA 
in the presence of UV-A, the photoproducts formed causing 
inhibition of cellular DNA synthesis [3]. It is believed that this 
mechanism explains the beneficial effect of PUV A in prolifer-
ative disorders like psoriasis. 
Methods are now available to measure 8-MOP blood levels 
[4-6] and it is thus possible to study 8-MOP and UV-A dose 
interrelations. A correlation between oral dose and serum levels 
of 8-MOP has not previously been demonstrated. Such a rela-
tionship, as well as a correlation between serum 8-MOP con-
centrations and the minimum phototoxic dose ofUV-A (MPD), 
has been questioned on the basis of isolated determinations in 
psoriatic patients [7,8]. Since the "skin type" of the patient, 
which reflects the individual sensitivity to ultraviolet radiation, 
also influences the dose relations in PUV A, this kind of com-
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parison should be performed within the same individual. Also, 
the range of 8-MOP serum concentrations is great in patients 
receiving the same dose in mg/kg bodyweight [6-9]. 
It is of interest to establish whether 8-MOP blood levels can 
be used. in monitoring the phototoxic reaction in PUV A. We 
therefore decided to study 8-MOP serum levels as a function of 
oral dose and to investigate the relation between serum levels 
and skin photosensitivity. 
MATERIALS AND METHODS 
Volunteers 
Eight healthy volunteers (5 males and 3 females; 23 to 48 yr), from 
whom informed consent had been obtained, participated in the study. 
None of the test persons had received any systemic medication for at 
least 5 days before the start of the study. 
Drug 
8-Methoxypsoralen (8-MOP), in 5 mg sugar-coated tablets, was 
kindly provided by AB Draco, Lund, Sweden. On the basis of body-
weight, psoralen doses of 0.3, 0.6 and 0.9 mg/ kg were calculated for 
each test person. 
Phototestin.g 
Six of the 8 volunteers completed the phototesting. Each individual 
participated in 3 tests, one on each 8-MOP dose. On the basis of the 
burning and tanning history the "skin type" of each volunteer was 
determined [10]. Two hours prior to the testing the 8-MOP dose was 
taken with a light meal. The phototesting was performed with a PUVA 
4000-equipment (Waldmann AG, Schwenningen, West Germany) emit-
ting mainly in the long-wave ultraviolet (UV-A) region with a peak at 
365 nm. Test doses of UV-A ranging from 0.5 J /cm2 to 20 J / cm2 were 
delivered to previously not sun-exposed skin on the buttocks. Doses 
were increased by a factor of approximately ../2. Circular test areas, 
diameter 20 mm, were used. Seventy-two hours later t he tests were 
read by one of the investigators (MB), and the lowest dose of UV-A 
giving a well-defined erythema (MPD) was established. This procedure 
was repeated for the other two 8-MOP doses with a minimum of 3 days 
elapsing between each test. The 3 doses were randomized, and the 
investigators reading the phototests did not know which 8-MOP dose 
had been given. The test persons were inquired about subjective side 
effects after each 8-MOP dose. 
8-MOP Serum Levels 
Immediately before phototesting a 5 ml blood sample was drawn 
the serum separated and kept at -22°C until analysed for 8-MOP. Th~ 
technique for measuring 8-MOP serum concentrations has been de-
scribed in detail elsewhere [6]. The serum samples were assayed by 
high pressure liquid chromatography (HPLC) . After adding ammid.in 
(8-isoamylenoxypsoralen, imperatorin, kindly supplied by AB Draco, 
Lund, Sweden) as internal standard, a 1 ml serum sample was extracted 
with benzene, the organic phase evaporated with nitrogen, and the 
residue redissolved in a small amount of the chromatographic solvent 
(methylene chloride : acetonitrile 95:5). A 20 JLI aliquot was injected 
into the chromatograph (Altex 330, Altex Scientific Inc., Berkely, 
California) equipped with a Partisil 10 microparticulate silica column 
(Whatman Inc., Clifton, New Jersey). The psoralens we.re detected 
with a UV detector at 254 nm (Altex 330). Calculations of serum levels 
were based on peak height measurements as described [6]. 
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Statistics 
For statistical evaluation the Student's t-test and regression analysis . 
was used. 
RESULTS AND DISCUSSION 
8-MOP Serum Levels 
Serum 8-MOP levels were a function of the oral dose for the 
dose range 0.3 to 0.9 mg/kg bodyweight in all 8 persons tested. 
The individual serum concentrations varied, but all curves 
approached linearity when plotted on a log-log scale (Fig lA). 
This variation in the position of the dose-response curves along 
the vertical axis indicates differences in absorption and metab-
olism of the drug between the test persons. A considerable 
individual variation in 8-MOP blood levels is well established 
[6-9]. 
Mean 8-MOP levels 2 hr after doses of0.3, 0.6 and 0.9 mg/kg 
were 25.9 (±7.2), 148.9 (± 24.2) and 311.4 (±55.6) ng/ml serum 
(mean and SEM) respectively (Fig 1B). 
The psoralen test doses were derived from the standard 
empirical8-MOP dose of 0.6 mg/kg bodyweight [10] by adding 
or subtracting 50%. In order to make the psoralen dosage more 
accurate 5 mg 8-MOP tablets were used instead of the regular 
10 mg tablets. The psoralen was taken with food in order to 
minimize nausea. Absorption of 8-MOP has been shown to 
improve somewhat when the drug is administered with food as 
compared to fasting conditions [11]. Side effects noted by the 
volunteers were usually moderate and transient, and as ex-
pected, more frequent with higher doses. Only one person 
complained of severe nausea on the 0.9 mg/kg dose. 
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FIG 1. Serum levels of 8-methoxypsoralen (ng/ml) following 3 dif-
ferent oral doses. Concentrations for each of 8 volunteers (A) and mean 
concentrations (B) (bars indicate SEM) are given. (One volunteer, nr. 
7, not tested on 0.9 mg/kg) . 
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FIG 2. Minimum phototoxic dose of UV-A (J/cm2 ) as a function of 
8-MOP serum concentration (ng/ml) in each of 6 volunteers who 
completed the phototesting on 3 different oral doses of 8-MOP. 
Phototesting 
Dose-response relations cannot be conveniently studied by 
keeping the 8-MOP dose constant and varying the UV-A dose 
since erythema cannot be easily quantitated. We instead chose 
to measure the minimum ph ototoxic dose of UV -A following 3 
different doses of 8-MOP. 
For each of the three 8-MOP doses the amount of UV -A 
energy required to produce a well-defmed minimal erythema 
(MPD) was established. When for each individual the UV-A 
dose was plotted against the serum level of 8-MOP, an inverse 
correlation was obtained with r values of 0.86-0.99 (0.92 ± 0.02, 
mean and SEM) (Fig 2). 
When investigating the relationship between 8-MOP serum 
level and minimum phototoxic dose ofUV-A one has to consider 
a third factor: the individual photosensitivity, which is related 
to factors such as degree of pigmentation and thickness of 
stratum corneum. This individual sensitivity influences the 
fraction of delivered UV dose reaching the appropriate levels of 
action in the skin. Variations of this kind as well as in 8-MOP 
serum levels on the same oral dose make single determinations 
in different individuals [7,8] unsuitable for dose-response stud-
ies in PUV A. Within each individual, however, an inverse 
correlation between psoralen levels and UV -A doses could be 
demonstrated for the dose range tested (Fig 2) . In an animal 
model the phototoxic response to psoralens was also dose-
dependent [12]. Recently, in a study on time-course relations, 
serum 8-MOP levels and the minimum phototoxic dose of UV-
A also correlated well [13). 
Reciprocity 
Psoralen phototoxicity is dependent on both drug and UV 
doses. For another phototoxic agent, chlorpromazine, evidence 
has been presented suggesting a reciprocal relationship between 
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Product of UV-A dose (J/cm2) and 8-MOP serum concentration (ng/ 
ml) at the MPD for each of 6 volunteers tested on 3 different oral 
doses of 8-MOP" 
Skin 8-MOP dose (mg/kg) Nr Sex/Age type 0.3 0.6 0.9 
1 M 36 II 221.7 470.2 524.2 
2 M 34 III 306.6 1320.9 1104.3 
3 M 49 II 282.0 315.7 419.5 
4 M 31 II 153.0 521.4 482.3 
5 F 24 II 182.0 478.8 511.8 
6 F 38 III 403.2 709.2 641.7 
M 258.1 636.6 614.0 
SEM ±37.5 ±146.3 ±102.6 
p <0.016 <0.05c NS<~ 
" Mean, SEM and p values are indicated, as well as sex, age and skin 
type of the subjects. 
b 0.3 vs 0.9. 
c 0.3 vs 0.6. 
d 0.6 vs 0.9. 
these 2 factors (14]. This means that within a certain dose range 
the amounts of UV-A and drug can be changed while still 
obtaining the same biological effect, as long as the product is 
kept constant. For the 2 higher 8-MOP doses the numerical 
products of UV-A dose and 8-MOP serum concentrations did 
not differ significantly, indicating a reciprocal relationship in 
this dose interval (Table). This did not hold true for the low 8-
MOP dose where the product was numerically smaller, and less 
UV-A energy was needed to obtain threshold erythema than 
would have been expected from extrapolation from the 2 higher 
8-MOP doses (Fig 2). The amount of UV-A energy delivered to 
the test sites was large (10- 20 J/cm2), however, and factors 
such as photoaddition or photoaugmentation [15,16] of suber-
ythemal UV -A doses could account for the · deviation of the 
dose-response curve. Furthermore, the light source used for 
testing emits a small amount of radiation below 320 nm. With 
regular UV-A doses this is of little significance but with large 
doses this fraction may contribute to the resulting erythema. 
Due to the wide inter-individual variation solitary 8-MOP 
serum measurements yield only very limited information. If 
repeated measurements are performed in the same individual, 
however, it can be demonstrated that the 8-MOP serum level 
correlates both with the psoralen dose administered and with 
the MPD ofUV-A. This supports the relevance of using 8-MOP 
serum concentrations in monitoring psoralen phototoxicity. 
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